By Reuters Staff
2 Min Read
FILE PHOTO: Woman holds vials labelled COVID-19 Coronavirus Vaccine over dry ice in this illustration taken, December 5, 2020. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
KUALA LUMPUR (Reuters) - Malaysia’s Solution Group Bhd said on Thursday it has signed a term sheet agreement with the government to supply 3.5 million doses of COVID-19 vaccine jointly developed by China’s CanSino Biologics Inc and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences.
The company, whose website shows it is an engineering as well as biopharmaceuticals business, said in a bourse filing that its wholly-owned unit Solution Biologics had signed the agreement on Jan. 29 with the Health Ministry.
KUALA LUMPUR (Feb 4): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Friday, Feb 5) include: My EG Services Bhd (MyEG), Solarvest Holdings Bhd, Green Packet Bhd, GHL System Bhd, Solution Group Bhd, Tropicana Corp Bhd, Reservoir Link Energy Bhd, CIMB Group Holdings Bhd and Ranhill Utilities Bhd.
My EG Services Bhd (
MyEG) said it will introduce an at-home saliva-based Covid-19 testing service in the Philippines this month the first of its kind in the Philippines market. The group called the Covid-19 test a safe, fast, convenient and non-invasive method that can greatly enhance accurate detection and subsequent early intervention.
Kalamazoo, MI, USA / WKZO | Everything Kalamazoo | 590 AM · 106.9 FM
Feb 4, 2021 6:38 AM
KUALA LUMPUR (Reuters) - Malaysia s Solution Group Bhd said on Thursday it has signed a term sheet agreement with the government to supply 3.5 million doses of COVID-19 vaccine jointly developed by China s CanSino Biologics Inc and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences.
The company, whose website shows it is an engineering as well as biopharmaceuticals business, said in a bourse filing that its wholly-owned unit Solution Biologics had signed the agreement on Jan. 29 with the Health Ministry.
The agreement will enable the subsidiary to enter into a definitive supply agreement to supply 3.5 million doses of the Recombinant Ad5-nCoV vaccine for the prevention of COVID-19, it said.
Talebula Kate
1 February, 2021, 7:31 am
FILE PHOTO: A technician works at a genetic testing laboratory of BGI, formerly known as Beijing Genomics Institute, in Kunming, Yunnan province, China December 26, 2018. REUTERS/Stringer
SYDNEY (Reuters) – BGI Group, the world’s largest genomics company, has worked with China’s military on research that ranges from mass testing for respiratory pathogens to brain science, a Reuters review of research, patent filings and other documents has found.
The review, of more than 40 publicly available documents and research papers in Chinese and English, shows BGI’s links to the People’s Liberation Army (PLA) include research with China’s top military supercomputing experts. The extent of those links has not previously been reported.
BGI Group's links to the People’s Liberation Army, which have not been previously reported, include research with China’s top military supercomputing experts.